All In Biotech

Drug Trial Radar · NCT07912593

A KRAS Inhibitor in Participants With Advanced Solid Tumors

A Phase 1/2, First-in-Human Study of ETX-929, a Pan-KRAS Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With KRAS-Altered Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Oct 22, 2026

Primary completion

Oct 30, 2028

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Ensem TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multi-center study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-929 in participants with advanced solid tumors harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.

Conditions

  • Metastatic Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Non-squamous, Non-Small Cell Lung Cancer
  • Endometrial Adenocarcinoma
  • Ovarian Adenocarcinoma
  • Primary Peritoneal Carcinoma

Interventions

  • ETX-929 dose escalationDrug

    ETX-929 is a pan-KRAS Inhibitor in the form of an oral capsule that will be taken once per day in 21-day cycles, to evaluate escalating dose levels.

  • ETX-929 dose escalation in combination with cetuximabDrug

    ETX-929 is a pan-KRAS Inhibitor in the form of an oral capsule. ETX-929 will be taken in combination with cetuximab in 28-day cycles, to evaluate escalating dose levels. EXT-929 is an oral capsule that will be taken once per day. Cetuximab will be administered intravenously every two weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate Safety and Tolerability of ETX-929 monotherapy in Part A and ETX-929 plus cetuximab combination therapy in Part BTime frame: First Cycle (21 days in Part A and 28 days in Part B)
  2. Evaluate Safety and Tolerability of ETX-929 monotherapy in Part A and ETX-929 plus cetuximab combination therapy in Part BTime frame: Average of 6 months
  3. Select the Recommended Phase 2 Dose(s) (RP2D)Time frame: Average of 6 months
  4. Evaluate efficacy of ETX-929 monotherapy and ETX-929 in combination with cetuximab at the RP2D(s) in Part B and Part DTime frame: Average of 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NEXT

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.